Pierre Perazzelli - Theratechnologies Vice President - Pharmaceutical Development
| TH Stock | CAD 1.74 0.06 3.57% |
President
Mr. Pierre Perazzelli is Vice President Pharmaceutical Development of Theratechnologies, Inc. A graduate of Universit Laval, Mr. Perazzelli was working in the pharmaceutical manufacturing industry for over 20 years. Throughout his career, he has held various positions in large pharmaceutical companies, including Bristol Myers Squibb and Abbott Laboratories, Ltd. He was Director of the LAB Laboratory, a research centre specializing in pharmaceutical formulation. He is also experienced in the production of generic drugs. Mr. Perazzelli joined us in 2000.
| Age | 62 |
| Address | 2015 Peel Street, Montreal, QC, Canada, H3A 1T8 |
| Phone | 514 336 7800 |
| Web | https://www.theratech.com |
Theratechnologies Management Efficiency
The company has return on total asset (ROA) of 0.1176 % which means that it generated a profit of $0.1176 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (11.1686) %, meaning that it generated substantial loss on money invested by shareholders. Theratechnologies' management efficiency ratios could be used to measure how well Theratechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Equity is likely to grow to 1.39, while Return On Tangible Assets are likely to drop (0.44). At this time, Theratechnologies' Non Current Assets Total are very stable compared to the past year. As of the 27th of November 2024, Other Assets is likely to grow to about 2.2 M, while Total Assets are likely to drop about 65.2 M.Similar Executives
| Found 6 records | PRESIDENT Age | ||
| Thomas Turner | Rogers Communications | N/A | |
| Philip Hartling | Rogers Communications | N/A | |
| Robert Depatie | Rogers Communications | 65 | |
| Mahes Wickramasinghe | Rogers Communications | 66 | |
| Colette Watson | Rogers Communications | N/A | |
| Bret Leech | Rogers Communications | N/A | |
Management Performance
| Return On Equity | -11.17 | ||||
| Return On Asset | 0.12 |
Theratechnologies Leadership Team
Elected by the shareholders, the Theratechnologies' board of directors comprises two types of representatives: Theratechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theratechnologies. The board's role is to monitor Theratechnologies' management team and ensure that shareholders' interests are well served. Theratechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theratechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MarieNoel Colussi, Vice President - Finance | ||
| Jovan Antunovic, Senior Vice President and Chief Commercial Office | ||
| Conor Walshe, General Manager - Theratechnologies Europe Limited | ||
| Sheila Frame, Independent Director | ||
| Paul Lvesque, CEO President | ||
| Philippe Dubuc, Chief Financial Officer, Senior Vice President | ||
| Paul Levesque, President, Chief Executive Officer, Director | ||
| Andrew Molson, Independent Director | ||
| Gerald Lacoste, Independent Director | ||
| LLB LLM, General Secretary | ||
| Dawn Svoronos, Independent Chairman of the Board | ||
| Pierre Perazzelli, Vice President - Pharmaceutical Development | ||
| LLB BA, VP Affairs | ||
| Denis Boucher, Vice President - Communications and Corporate Affairs | ||
| H MSc, Vice Resources | ||
| Christian Marsolais, Senior Vice President - Scientific Affairs and Alliances | ||
| John Leasure, Global Officer | ||
| Paul Pommier, Independent Director | ||
| Gilles Cloutier, Independent Director | ||
| Gary Littlejohn, Independent Director | ||
| Elif McDonald, Director Relations | ||
| Jocelyn Lafond, Vice President - Legal Affairs, Corporate Secretary | ||
| Alain Trudeau, Independent Director | ||
| MBA MBA, Senior CFO | ||
| Dale Weil, Independent Director |
Theratechnologies Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theratechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.17 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 106.76 M | ||||
| Shares Outstanding | 45.98 M | ||||
| Shares Owned By Insiders | 1.22 % | ||||
| Shares Owned By Institutions | 51.56 % | ||||
| Number Of Shares Shorted | 23.02 K | ||||
| Price To Earning | (52.28) X |
Pair Trading with Theratechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Theratechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Theratechnologies will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Theratechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Theratechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Theratechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Theratechnologies to buy it.
The correlation of Theratechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Theratechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Theratechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Theratechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theratechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Theratechnologies Stock, please use our How to Invest in Theratechnologies guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.